Pharmaceutical stocks have recently separated themselves from the broader market, and the group has become an increasingly important source of leadership within healthcare. Eli Lilly is the bellwether in the space and has already broken out to all-time highs, and that strength is showing up in sector-level proxies like the iShares U.S. Pharmaceuticals ETF (IHE) . With pharma momentum shifting positive in absolute and relative terms, we see a favorable setup developing for other large names to follow, including Johnson & Johnson . IHE is extending its cyclical uptrend with a push to new highs, and the move is being confirmed by a weekly moving average convergence/divergence, or MACD, crossover that reflects renewed intermediate-term momentum. Lilly is roughly 25% of IHE, so its breakout is a meaningful tailwind for the ETF, but IHE's strength suggests leadership is broadening beyond a single name. On the relative front, the ratio of IHE to the SPX is rebounding off support from its 200-day (40-week) MA, suggesting that pharma is positioned for additional outperformance in the weeks ahead. The ratio is also well positioned in the long-term based on the rising slope of the 40-week MA. Johnson & Johnson is also improving, and the charts suggest it has the potential to reassert leadership within pharma after a period of consolidation. The weekly stochastics have flashed an oversold upturn, a constructive development that often coincides with an intermediate-term low. Momentum is also improving, as JNJ continues to see consecutive upticks in the weekly MACD histogram. From a key levels perspective, initial support is defined by the rising 200-day MA (~$213), while the highs near $249 act as resistance. The daily chart adds an important near-term catalyst. JNJ has an active countertrend "buy" signal from the DeMARK Indicators®, and the daily MACD is back on a "buy" signal, reinforcing the likelihood of upside continuation in the near term. With JNJ breaking back above its 50-day MA and into the daily cloud, the momentum shift has become more evident. The relative trend is another reason JNJ is worth highlighting here. The JNJ vs. SPX Index ratio has seen a countertrend cyclical upmove since the beginning of 2025, defined by a series of higher lows. This countertrend strength comes within a multiyear downtrend, but the cyclical upmove appears to have staying power. Now, with the ratio oversold as it approaches support at its 40-week MA, JNJ is at a relative proving ground and appears poised for another leg higher in both absolute and relative terms. Pharma leadership is being reinforced by IHE's push to new highs and a fresh weekly MACD crossover, and JNJ is showing the types of intermediate-term signals that can precede rotation into other large-cap bellwethers. With support defined at the 200-day MA and resistance near $249, the risk-reward profile in JNJ is becoming clearer as momentum turns higher. —Katie Stockton with Will TamplinAccess research from Fairlead Strategies for free here . DISCLOSURES: All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, or its parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer. Fairlead Strategies Disclaimer: This communication has been prepared by Fairlead Strategies LLC ("Fairlead Strategies") for informational purposes only. This material is for illustration and discussion purposes and not intended to be, nor construed as, financial, legal, tax or investment advice. You should consult appropriate advisors concerning such matters. This material presents information through the date indicated, reflecting the author's current expectations, and is subject to revision by the author, though the author is under no obligation to do so. This material may contain commentary on broad-based indices, market conditions, different types of securities, and cryptocurrencies, using the discipline of technical analysis, which evaluates the demand and supply based on market pricing. The views expressed herein are solely those of the author. This material should not be construed as a recommendation, or advice or an offer or solicitation with respect to the purchase or sale of any investment. The information is not intended to provide a basis on which you could make an investment decision on any particular security or its issuer. This document is intended for CNBC Pro subscribers only and is not for distribution to the general public. Certain information has been provided by and/or is based on third party sources and, although such information is believed to be reliable, no representation is made with respect to the accuracy, completeness, or timeliness of such information. This information may be subject to change without notice. Fairlead Strategies undertakes no obligation to maintain or update this material based on subsequent information and events or to provide you with any additional or supplemental information or any update to or correction of the information contained herein. Fairlead Strategies, its officers, employees, affiliates and partners shall not be liable to any person in any way whatsoever for any losses, costs, or claims for your reliance on this material. Nothing herein is, or shall be relied on as, a promise or representation as to future performance. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. Opinions expressed in this material may differ or be contrary to opinions expressed, or actions taken, by Fairlead Strategies or its affiliates, or their respective officers, directors, or employees. In addition, any opinions and assumptions expressed herein are made as of the date of this communication and are subject to change and/or withdrawal without notice. Fairlead Strategies or its affiliates may have positions in financial instruments mentioned, may have acquired such positions at prices no longer available, and may have interests different from or adverse to your interests or inconsistent with the advice herein. Any investments made are made under the same terms as nonaffiliated investors and do not constitute a controlling interest. No liability is accepted by Fairlead Strategies, its officers, employees, affiliates, or partners for any losses that may arise from any use of the information contained herein. Any financial instruments mentioned herein are speculative in nature and may involve risk to principal and interest. Any prices or levels shown are either historical or purely indicative. This material does not take into account the particular investment objectives or financial circumstances, objectives or needs of any specific investor, and are not intended as recommendations of particular securities, investment products, or other financial products or strategies to particular clients. Securities, investment products, other financial products or strategies discussed herein may not be suitable for all investors. The recipient of this information must make its own independent decisions regarding any securities, investment products or other financial products mentioned herein. The material should not be provided to any person in a jurisdiction where its provision or use would be contrary to local laws, rules, or regulations. This material is not to be reproduced or redistributed absent the written consent of Fairlead Strategies.
<small>Source: CNBC</small>
